

## Listing of Claims

- 1-29. (canceled)
30. (Currently amended) A fusion immunotoxin comprising a single-chain variable region of an anti-CD3 antibody linked to a toxin moiety, wherein the anti-CD3 antibody is UCHT1, wherein the diphtheria toxin moiety is a truncation of native diphtheria toxin at the carboxy terminus, and wherein about ~~150~~152-145 carboxy terminal amino acid residues are truncated from the native diphtheria toxin moiety.
31. (previously presented) The fusion immunotoxin according to claim 30, wherein the truncated toxin moiety is DT390.
32. (previously presented) The fusion immunotoxin according to claim 31, comprising DT390 linked via its carboxy terminus, optionally via a linker, to the single-chain variable region of the anti-CD3 antibody.
33. (previously presented) The fusion immunotoxin according to claim 32, wherein the single-chain variable region of the anti-CD3 antibody comprises the variable light domain linked via its carboxy terminus to the variable heavy domain, optionally via a linker.
- 34-36. (canceled)
37. (previously presented) A fusion immunotoxin, consisting of DT390 linked via its carboxy terminus through a linker to the variable light domain of UCHT1 which is linked via its carboxy terminus through a (Gly<sub>4</sub>Ser)<sub>3</sub> (SEQ ID NO:15) linker to the variable heavy domain of UCHT1.

38. (previously presented) A method for inhibiting rejection of transplanted tissue or organs in a subject, comprising administering to the subject an immunotoxin according to claim 30.
39. (currently amended) A method for treating a subject with a T-cell mediated ~~autoimmune~~ disease, comprising administering to the subject an immunotoxin according to claim 30.
- 40-42. (canceled)
43. (New) A method for inhibiting rejection of transplanted tissue or organs in a subject, comprising administering to the subject an immunotoxin according to claim 37.
44. (New) A method for treating a subject with a T-cell mediated disease, comprising administering to the subject an immunotoxin according to claim 37.
45. (New) A fusion immunotoxin comprising a single-chain variable region of an anti-CD3 antibody linked to a toxin moiety, wherein the anti-CD3 antibody is UCHT1, wherein the diphtheria toxin moiety is a truncation of native diphtheria toxin at the carboxy terminus, and wherein about 152 or 145 carboxy terminal amino acid residues are truncated from the native diphtheria toxin moiety.
46. (New) The method of claim 44, wherein the T-cell mediated disease is graft versus host disease (GvHD).
47. (New) The method of claim 44, wherein the T-cell mediated disease is an autoimmune disease.